natgillin/translations-raw huggingface dataset:
INDUSTRIAL APPLICABILITY The compounds of the present invention have the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and are therefore effective in reducing or treating central nervous system such as head trauma and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia or after-effects of these diseases, or other diseases against which the compounds of the present invention are considered effective. 
Sredstvo za poticanje aksonskog izrastanja i/ili poticanje angiogeneze ili terapeutsko sredstvo za liječenje ili smanjenje bolesti uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave 1 ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca i bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti, pomoću poticanja aksonskog izrastanja i/ili poticanja angiogeneze, naznačen time da kao aktivni sastojak sadrži spoj prema zahtjevima 1 do 4, ili njegovu farmaceutski prihvatljivu sol.
In certain embodiments, the pharmaceutically effective concentration of PRG4 protein is in a range of 10-10,000 ug/mL, preferably 50-5,00 mg/mL, and more preferably 100-300 mg/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 10-10,000 ug/mL.
In one embodiment of the invention there is provided a process comprising the steps of monitoring the temperature of the heated liquid in the buffer tank and maintaining the temperature of the heated liquid in the buffer tank at a desired temperature. 
Postupak prema zahtjevu 8 gdje taj postupak obuhvaća korake praćenja temperature zagrijane tekućine u međuspremniku i održavanje temperature zagrijane tekućine u međuspremniku na željenoj temperaturi.
The reaction is allowed to proceed for 90 min on a platform shaker at room temperature and then terminated by placing assay plate on a Millipore vacuum manifold (Millipore, Bedford, Mass.), aspirating the solvent, and washing wells twice with 200 ul ice cold phosphate buffered saline (PBS). 
Reakciju se ostavlja da protječe 90 minuta na platformnoj tresilici, na sobnoj temperaturi, a prekinuta je stavljanjem ploče za ispitivanje na vakuumski odsisnik Millipore (Millipore, Bedford, MA), uz odsisavanje otapala, te ispiranje jažica, dvaput, s 200 ul ledeno hladnom fosfatno puferiranom fiziološkom otopinom (PBS).
Cortexolone-17a-propionate in hydrate crystalline form IV according to any one of claims 21 to 22 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
Sigma ligand according to claim 1, wherein the pain is selected from acute and/or chronic pain developed as a consequence of bone cancer, preferably neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure. 
< Sigma ligand, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se bol bira između akutne ifili kronične boli koja se pojavljuje kao posljedica raka kostiju, po mogućnosti neuropatske boli, neuralgije, alodionije, kauzalgije, hiperalgezije, hiperestezija, hiperpatije, neuritisa ili neuropatije kirurškog zahvata.
The method of claim 19, wherein the hydrolysis of N-(3-(2,6-dioxopiperidin-3-yl)-2-methyl-4-oxo-3,4-dihydroquinazolin-5-yl)formamide is conducted in the presence of an acid catalyst. 
Postupak u skladu s patentnim zahtjevom #8, naznačen time što dodatno uključuje korak hidrolize N-(3-(2,6-dioksopiperidin-3-il)-2-metil-4-okso-3,4-dihidrokinazolin-5-iD)formamida do 3-(5-amino-2-metil-4-oksokinazolin-
The plant cultivation system according to claim 1, wherein said water impermeable material layer is a synthetic resin film. 
Sustav za uzgoj biljaka prema zahtjevu 1, gdje je vodonepropusni materijal (2) sloj sintetičke smole.
X' is a second halide anion which is different from the first halide anion; and z is greater than 0 and less than 1, and preferably z is from 0.05 to 0.95. 
X je drugi halogenidni anion koji je različit od prvog halogenidnog aniona i zje veći od 0 1 manji od 1, a poželjno je da je z od 0, 05 do 0, 95.
Use of the oligonucleotide as defined in any one of claims 1 to 4, the vector of claim 5, or the pharmaceutical composition of claim 7 for modulating splicing of the dystrophin pre-mRNA in a human myogenic cell or muscle cell in vitro, or for the preparation of a medicament for the treatment of a DMD or BMD patient. 
In vitro metoda za induciranje ili promoviranje preskakanja eksona 45 pre-mRNA distrofina u izoliranoj stanici navedenog pacijenta, metoda obuhvaća opskrbljivanje navedene stanice besmislenim oligonukleotidom kako je definirano u bilo kojem od patentnih zahtjeva 1-14, vektor iz patentnog zahtjeva 15, ili farmaceutski sastav iz patentnog zahtjeva 16.
An inhaler according to any preceding claim, wherein the inhaler is a breath-actuated metered-dose inhaler. 
Inhalator u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je inhalator disanjem-potaknuti inhalator s mjerenjem doze.
The method of claim 10 wherein the dosage form at first commercial sale contains no more than about 3% by weight of mono-POC PMPA. 
Postupak prema patentnom zahtjevu 10, naznačen time što oblik doze prilikom prve komercijalne prodaje sadrži ne više od oko 3 težinska % mono-POC PMPA.
Pharmaceutical composition according to any one of claims 1, 4 or 5, wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension. 
Farmaceutski sastav prema bilo kojem zahtjevu 1, 4, 5 ili 6, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
The method of claim 5, wherein the anti-TNFa antibody or antigen-binding fragment thereof comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5, optionally wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4. 
Postupak prema zahtjevu 5, naznačen time što anti- TNFa protutijelo ili njegov fragment koji veže antigen sadrži ne-humanu varijabilnu regiju koja sadrži sekvencu aminokiselina koja se bira iz skupine koja se sastoji od SEQ ID NO: 3 i SEQ ID NO: 5, proizvoljno pri čemu ne-humani varijabilna regija sadrži polipeptid kodiran sekvencom nukleinske kiseline koja se bira iz skupine koja se sastoji od SEQ ID NO: 21 SEQ ID NO: 4.
a media for growing the viral cultures, wherein the EO-PO block copolymers accelerate growth of viral cultures. The composition of claim 1, wherein the viral cultures are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Pestivirus, Herpes virus, and Poxvirus. 
Spoj sukladno patentnom zahtjevu 1, gdje su kulture virusa odabrane iz grupe koju čine flavi virus, toga virus, korona virus, rabdo virus, filo virus, paramiksovirus, ortomiksovirus, bunyavirus, arenavirus, retrovirus, hepadnavirus, pestivirus, pikorna virus, calicivirus, reovirus, parvovirus, papovavirus, adenovirus, herpes virus i virus boginja.
A method according to embodiment 1, wherein the volume fraction of said milling beads in said in the milling chamber is in the range 60-95 % such as 70-90 %, and preferably the volume fraction of said milling beads in said milling process is in the range 75-85 %, such as 80-85 %. 
Postupak prema zahtjevu 1. naznačen time da je volumenski udio navedenih zrnaca za mljevenje (9) u navedenoj komori za mljevenje (4; 4A; 4B; 4C) u rasponu od 60-95 % kao što je 70-90 %, te poželjno daje volumenski udio navedenih zrnaca za mljevenje u navedenom postupku mljevenja u rasponu od 75-85 %, kao što je 80-85 %.
The present invention also relates to a method of producing a powder adhesive as described above comprising the steps of: mixing expanded perlite, cement, and a dispersible polymer powder, in any order; wherein at least 30% volume of the sand-free powder adhesive is the expanded perlite. 
Pripravak ljepila bez pijeska koji sadrži: cement; disperzibilni polimerni prah; i prošireni perlit, pri čemu je najmanje 30% volumena ljepila bez pijeska prošireni perlit; naznačen time što je spomenuti cement u omjeru između 800-950% mase spomenutog proširenog perlita.
An antibody which is capable of binding to Interleukin 11 (IL-11) or IL-11 receptor a (IL-11Ra) and inhibiting IL-11 mediated signalling, for use in a method of treating or preventing scleroderma, nephrogenic systemic fibrosis or cutis keloid. 
Protutijelo za uporabu u postupku liječenja ili prevencije fibroze prema zahtjevu 1, naznačeno time, da je protutijelo sposobno za prevenciju ili redukciju vezivanja IL-11 na IL-11 receptor.
The composition of any one of clauses 34-36, characterized by at least one of the following features: 
(b) naznačena najmanje jednom od slijedećih karakteristika:
isolating the compound of formula (I) from the reaction mixture. 
(iv) izolacija spoja čija je formula (I) iz reakcijske mješavine.
Results at T = 25 deg C A process for generating a main fuel composition comprising methanol and water and not more than 20% by weight dimethyl ether, and a fumigant comprising dimethyl ether, the process comprising: 
Postupak za pripremu i provedbu smjese goriva koja sadrži metanol i vodu i ne više od 20% težine dimetil etera, i fumigant koji sadrži dimetil eter, naznačen time da taj postupak obuhvaća:
For example, the composition may comprise sodium chloride in an amount of 0.5 to 5 g, for example 1.5 to 4 g, for example 2.0 to 3.5 g, for example 2.8 g or 3.2 g. For example, the composition may comprise potassium chloride in an amount of 0.5 to 5 g, for example 0.5 to 3.5 g, for example 0.75 to 2.5 g, for example 0.75 to 1.5 g, for example 1.0 to 1.4 g, for example 1.2 g or 1.3 g. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što sadrži natrijev klorid u količini od 1,5 do 4 g, primjerice 2 do 3,5 g; primjerice 2,8 g ili 3,2 g, te kalijev klorid u količini od 0,5 do 5 g, primjerice u koncentraciji od 0,5 do 3,5 g primjerice 0,75 do 1,5 g, primjerice 1,0 do 1,4 g; primjerice 1,2 g ili 1,3 g.
The starting point for the sequence of reactions in Scheme 1 is commercially available tetrabenazine (IV) which is a racemic mixture of the RR and SS optical isomers of tetrabenazine. 
Polazna točka niza reakcija u Shemi 1 je komercijalno raspoloživ tetrabenazin (IV) koji je racemična smjesa RR i SS optičkih izomera tetrabenazina.
A crystalline hydrate of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride having the formula wherein the hydrate contains 1.85 to 2.2 molecules water per molecule (I). 
Kristalni hidrat 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida koji ima formulu [image] naznačen time da hidrat sadrži 1.85 do 2.2 molekula vode po molekuli (I).
Furthermore, the device can most easily be implemented as an engraving in a polymer-bonded body of permanent-magnetic material (Plastoferrite). 
Osim toga, dotični se uređaj vrlo jednostavno može izvesti kao gravura u polimerom spojenom tijelu od permanentno magnetskog materijala (Plastoferrite).
A method of controlling undesirable vegetation in an aquatic environment, which comprises broadcasting, spraying or adding an herbicidally effective amount of the composition of claim 1, to the aquatic environment either before emergence or after emergence of the undesirable vegetation. 
Postupak kontroliranja nepoželjnog raslinja u vodenom okolišu, naznačen time što se sastoji u rasijavanju, prskanju ili dodavanju herbicidno djelotvorne količine pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 12 u vodeni okoliš bilo prije ili nakon pojave nepoželjnog raslinja.
The compound of claim 1, wherein the moiety -Y1-R2 is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je skupina -Y1-R2 odabrana iz skupine koju čine: [image] [image] [image] [image]
The subject invention also provides a the pharmaceutical composition comprising crystalline R(+)-N-propargyl-1-aminoindan and a pharmaceutically acceptable carrier. The pharmaceutical composition may be formulated for transdermal application. 
Farmaceutski sastav, naznačen time, da sadrži kristalni R(+)-N-propargil-1-aminoindan prema jednom od patentnih zahtjeva 1-3 i farmaceutski prihvatljivi nosilac.
In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy in particular for the treatment of a disease mediated by CRTh2 such as asthma or rhinitis. 
(D 2. < Spoj formule (I) prema zahtjevu 1 naznačena time za se koristi kod terapije. 3. Upotreba spoja formule (1), ili njegove farmaceutski prihvatljive soli ili solvata, kako je definiranu u zahtjevu 1 za proizvodnju lijeka za upotrebu kod liječenja bolesti posredovanih s CR'Th2.
The heterodimeric antibody of claim 9, wherein the positively charged amino acid residue substitutions in the CH3 domain of the first heavy chain at positions 366 and 351 are both lysine, and the negatively charged amino acid substitutions in the CH3 domain of the second heavy chain at positions 351 and 368 are each aspartic acid (D) or glutamic acid (E). A heterodimeric antibody comprising two heavy chains with CH3 domains wherein, (i) the CH3 domain of the first heavy chain comprises a substitution of the amino acid residue at position 366 as compared to wildtype and according to the EU numbering system, by a positively charged amino acid residue, and the CH3 domain of the second heavy chain comprises substitutions of the amino acid residues at positions 351 and 368 as compared to wildtype and according to the EU numbering system, by negatively charged amino acid residues; or 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
the remainder the crosslinked cation exchange polymer, with the weight percents based on the total weight of linear sugar alcohol, water and polymer. 
ostatak je umreženi polimer za kationsku izmjenu, gdje su maseni postotci u odnosu na ukupnu masu ravnolančanog šećernog alkohola, vode i polimera.
The method of embodiment 5, wherein said antibody is selected from the group consisting of the antibody produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. 
Monoklonalno antitijelo prema zahtjevu 1, gdje je navedeno antitijelo odabrano iz grupe koja se sastoji od monoklonalnog antitijela CHIR-5.9 koje se dobiva iz hibridomske stanične linije pohranjene kod tvrtke ATCC kao patentna pohrana br.
The method of claim 3, wherein the proliferation and/or survival of cells derived from the cancer is sensitive to phenylalanine restriction or depletion. 
Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu je proliferacija i/ili preživljenje stanica izvedenih iz raka osjetljivo na restrikciju ili depleciju fenilalanina.
A method of operating a batch mixer for producing first and second numbers of mixtures from first and second numbers of batches of materials to be mixed in said batch mixer, said batch mixer comprising: 
Postupak rada sa šaržnom miješalicom (10), radi proizvodnje prvog i drugog broja smjesa iz prvog i drugog broja šarža materijala koje treba pomiješati u navedenoj šaržnoj miješalici (10), gdje navedena šaržna miješalica (10) sadrži:
o is free of surfactants with the exception of polysorbate 80 or comprises one or more of said surfactants (excluding polysorbate 80) in a (collective) concentration of at most 1 mM; and/or 
o je bez arginina; o je bez amino kiselina; o je bez surfaktanta uz iznimku polisorbata 80; i o je bez fosfatnih puferskih sredstava/sustava.
Method for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is 6% by weight of protein or lower, the % of aggregate formation as determined by SE-HPLC, said method comprising the step of atomizing a composition comprising an aqueous carrier and a polypeptide comprising one or more immunoglobulin single variable domains at a concentration of 1 mg/mL to 200 mg/mL, wherein: 
Postupak za pripravu aerosola imunoglobulinskih pojedinačnih varijabilnih domena pri čemu količina stvaranja agregata iznosi 6 masenih % proteina ili niža, % stvaranja agregata je kako je određeno pomoću SE-HPLC, navedeni postupak sadrži korak atomiziranja pripravka koji sadrži vodeni nosač i polipeptid sadrži jednu ili više imunoglobulinskih pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, naznačen time što:
determining a blood GLP-1 level in a biological sample obtained from a mammal, said mammal having been administered with a GPR119 agonist; wherein the ability of the GPR119 agonist to increase a blood GLP-1 level in the mammal is indicative of the agonist being a GLP-1 secretagogue. 
(a) određivanje nivoa GLP-I u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen GPR119 agonist; pri čemu je sposobnost GPR119 agonista da poveća nivo GLP-1 u krvi u sisavcu indikativna da je agonist GLP-I sekretogog.
The method of any preceding clause, wherein up to one of the possible media items is selected for output based on previous output of at least one of the possible media items by the receiver. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se najviše jednu od mogućih medijskih točaka bira za izlaženje na osnovi prethodnog izlaženja najmanje jedne od mogućih medijskih točaka od strane prijemnika (1).
Summary of the Invention 
«» PRIJEVOD PATENTNIH ZAHTJEVA EUROPSKOG PATENTA
any substituted or unsubstituted aryl group; W is selected from the group consisting of a hydroxyl group, a glycerol molecule bound to an additional general formula (I) compound forming a diglyceride, or a glycerol molecule bound to two additional general formula (I) compounds forming a triglyceride; 
W se bira iz skupine koju čine hidroksilna skupina, molekula glicerola vezana na dodatni spoj opće formule (1), tvoreći diglicerid, ili molekula glicerola vezana na dva dodatna spoja opće formule (I), tvoreći triglicerid; i njihove soli, te solvati;
Typically, the vaccine contains the compound according to the invention in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 ug, or, alternatively, e.g. 100 fmol to 10 umol, preferably 10 pmol to 1 umol, in particular 100 pmol to 100 nmol. 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se najmanje jedan peptid ili polipeptid nalazi u sastavu u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng do 100 ug.
administering a vascular endothelial growth factor-A (“VEGF-A”) protein into the cerebrospinal fluid of the subject for up to at least 4 weeks at a dose within a range between 0.01 ug/kg/day and 0.6 ug/kg/day of the subject's body mass, 
Čimbenik rasta vaskularnog endotela VEGF165 za uporabu u liječenju bolesti motoneurona, naznačen time, da se rečeni VEGF 165 neprekidno primjenjuje i to najmanje 4 tjedna od početka uzimanja u dozi u omjeru između 0.01 tt/kg/day and 0.6 Pe/kg/dan.
A channelrhodopsin, comprising the light-inducible ion channel according to claims 1-6 and a retinal or retinal derivative, preferably wherein the retinal derivative is selected from the group consisting of 3,4-dehydroretinal, 13-ethylretinal, 9-dm-retinal, 3- hydroxyretinal, 4-hydroxyretinal, naphthylretinal; 3,7,11 -trimethyl-dodeca-2,4,6,8, 10- pentaenal; 3,7-dimethyl-deca-2,4,6,8-tetraenal; 3,7-dimethyl-octa-2,4,6-trienal; and 6-7 rotation-blocked retinals, 8-9 rotation-blocked retinals, and 10-11 rotation-blocked retinals. 
Kanalski rodopsin, obuhvaća ionski kanal induciran svjetlom u skladu s patentnim zahtjevima 1-6 i retinal ili derivat retinala, pri čemu je poželjno derivat retinala odabran iz grupe koja se sastoji od 3,4-dehidroretinala, 13- etilretinala, 9-dm-retinala, 3-hidroksiretinala, 4-hidroksiretinala, naftilretinala; 3,7,11-trimetil-dodeka-2,4,6,8,10- pentaenala; 3,7-dimetil-deka-2,4,6,8-tertaenala; 3,7-dimetil-okta-2,4,6-trienala 1 6-7 rotacijski blokiranih retinala, 89 rotacijski blokiranih retinala i 10-11 rotacijski blokiranih retinala.
to 50 wt.%, particularly 5 to 40 wt.% and preferably 10 to 20 wt.% of said at least one active agent; 
(a) 1 do 50 masenih %, posebno 5 do 40 masenih % i poželjno 10 do 20 masenih % navedene najmanje jedne djelatne tvari;
SEBS elastomer materials with similar properties to these would also be suitable. 
SEBS elastomerni materijali koji imaju slična svojstva kao i ovi, također bi mogli biti prikladni.
The compound or salt according to claim 1 wherein R3 represents a heteroaryl group selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, and thiadiazolyl, each of which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of methyl, bromo, chloro, fluoro, CHF2, hydroxy, amino, and —NHCH2CO2H. 
Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što R* predstavlja heteroarilnu skupinu, koju se bira iz skupine koju čine piridinil, pirimidinil, pirazinil, piridazinil, tiazolil, izotiazolil, te tiadiazolil, od kojih je svaki izborno supstituiran s 1 ili 2 supstituenta, koje se neovisno bira iz skupine koju čine metil, brom, klor, fluor, CHF>, hidroksi, amino, te -NHCH;CO:H.
The fishhook according to claim 1, characterized in that a smaller number of grooves are formed in a small-sized hook. 
Udica prema zahtjevu 1, naznačena time da se manji broj udubljenja (3) formira kod udice manje veličine.
The elongate wick of claim 25 wherein the polymeric material is a thermoset polymer. 
Izduženi fitilj (30) prema zahtjevu 22, pri čemu je polimerni materijal termostvrdnjujući polimer.
The compound or salt for use according to claim 35, wherein said corticosteroid is prednisone. 
Spoj ili sol prema zahtjevu 48 naznačen time da navedena bolest je psorijaza.
The method of claim 8, wherein the plant strengthener is applied before the stress event to be expected. 
Postupak prema zahtjevu 13, naznačen time da je osnaživač bilja apliciran prije očekivanog stresnog događaja.
Preferably, the aerosol forming substances will include a mixture of a high boiling, low vapor pressure substance and a low boiling, high vapor pressure substance. 
Poželjno će supstance za formiranje aerosola uključivati smjesu supstance niskog parnog tlaka i visoke točke vrelišta 1 supstance visokog parnog tlaka i niske točke vrelišta.